## PHARMAPACT REGULATORY PROPOSALS FOR NATURAL HEALTH AND THERAPEUTIC SUBSTANCES

(Official Release Version.ST/PP-22/7/99)

-FOOD-

FOOD CONTROL DIRECTORATE

## ---JURISDICTION---

**JOINT** 

-MEDICINE-

MEDICINES REGULATORY AUTHORITY

| ACT 54/1972 (FCD)   |   | AUTHORITY  | ACT 132/1998 (SAMMDRA)   |  |  |
|---|---|--|--|--|--|
| ` '   |   | (COMMITTEE)  | Natural Therapeutic Substances   |  |  |
| Natural Health Substances   |   | <u>Controversial</u>   | natural Therapeutic Substances   |  |  |
|   |   | <u>Intermediaries</u><br>←→                                    |  |  |  |
| HEALTH FOODS  | <u>DIETARY</u>  | <del></del>  | <u>COMPLEMENTARY</u>   | ORTHODOX (OND)   |  |
| & BEVERAGES (HFB)<br>TRADITIONAL REMEDIES                                   | SUPPLEMENTS (DS)<br>TRADITIONAL REMEDIES                              | <u>CATEGORIES</u><br>←→  | MEDICINES (CM) TRADITIONAL MEDICINES                                   | NATURAL DRUGS TRADITIONAL MEDICINES                            |  |
| Vegetable/mineral/animal  | Vegetable/mineral/animal  | <u>SUBSTANCES</u>  | Chemical, phyto-chemical,  | Chemical, phyto-chemical,                                      |  |
| with structure - function   | with structure - function   |  | mineral & animal, with self  | mineral & animal, including                                    |  |
| claims & / or <u>improving</u>  | claims & / or <u>improving</u>  |  | & non self -limiting disease   | treatment of <u>life-threatening</u>                           |  |
| all conditions of ill-health.   | self-limiting conditions.   | SPECIFIC<br>PARAMETERS   | <u>treatment</u> claims.<br><u>Life-threatening</u> diseases           | & emergency medicine. Fast-track compassionate &               |  |
| <u>Unlimited disease</u><br>risk-reduction claims.                          | Self-limiting condition risk-reduction claims.                        | <u>PARAMETERS</u>  | strictly only <u>as adjuvant.</u>                                      | investigational new drugs.                                     |  |
| (substance-specific)  | (substance-specific)  | $\downarrow\downarrow\downarrow\downarrow\downarrow\downarrow$ | (product-specific)   | (product-specific)   |  |
| ( <u>substance</u> specific)  | (substance specific)  |  | <u></u> 1 /  |  |  |
| Nutritional,  | Nutritional,  |  | Pharmacological,   | Pharmacological.   |  |
| phyto-chemical,   | phyto-chemical,   | Predominant  | phyto-chemical, nutritional,   | phyto-chemical, nutritional,                                   |  |
| psychological (placebo).  | psychological (placebo).  | <b>Physiological</b>   | psychological (placebo).   | psychological (placebo).                                       |  |
| Incidental pharmacologically  | No incidental or deliberate   | <u>Action</u>  | Substances scheduled on the  | Substances scheduled on the                                    |  |
| related health claims strictly  | pharmacologically related   | Claim & risk   | basis of <u>high risk of adverse</u><br>reactions, irrespective of the | basis of significantly <u>high risk</u>                        |  |
| limited to indisputable traditional foods/beverages.                        | <u>health claims</u> whatsoever.<br>Strictly reserved for C M.        | limitations  | absence of any health claims.  | of life-threatening adverse reactions. Banned substances.      |  |
| traditional foods/ beverages.   | Strictly reserved for C M.  |  | v  |  |  |
|   |   |  |  |  |  |
| Scientific evidence-based.  | Scientific evidence-based.  | <b>Efficacy</b>  | Scientific evidence-based.   | Scientific evidence-based.                                     |  |
| Limited Clinical Trials,  | Limited Clinical Trials,  | Qualifying   | Limited Clinical Trials,   | Randomised Clinical Trials                                     |  |
| Experimental Laboratory or Epidemiological Data.                            | Experimental Laboratory or Epidemiological Data.                      | Criteria   | Experimental Laboratory & Epidemiological Data.                        | & <u>Experimental</u> Laboratory Data. Compassionate trials.   |  |
| Evidence to exceed placebo.   | Evidence to exceed placebo.   |  | Evidence to exceed placebo.  | Evidence to exceed placebo.                                    |  |
| E 10 64 64 1 1  | Earl on Dhamasantical   |  | Food on Dhamas and asl   | Discussion Cofee CAI   |  |
| <b>Food Safety Standards.</b> Not to exceed that applicable to              | Food or Pharmaceutical Safety Standards.                              | Cofoty   | Food or Pharmaceutical<br>Safety Standards.                            | Pharmaceutical Safety Stds. Current standards applying to full |  |
| the most similar foods &  | Appropriate to the substances,  | Safety<br>Criteria   | Appropriate to the action, degree                                      | registration. (LD/TD50)  |  |
| appropriate to suggested use.   | degree of processing & dose.  | Criteria   | of processing & dose.  | All products to be re-evaluated.                               |  |
| Food Quality.   | Food & or moderate  |  | Food GMP up to high  | Pharmaceutical GMP.  |  |
| Appropriate to the substances & the degree of processing.                   | Pharmaceutical GMP.   |  | Pharmaceutical GMP.  | Appropriate to the substances &                                |  |
| Expiry dates if appropriate.  | Appropriate to the substances & the degree of processing.             | <b>Quality</b>   | Appropriate to the substances & the degree of processing.              | the degree of processing.<br>Highly stringent expiry dates,    |  |
| Not to exceed that applicable to  | Also claim related expiry dates,                                      | Criteria   | More stringent expiry dates,   | stability tests, if appropriate.                               |  |
| the most similar foods.   | stability tests, if appropriate.                                      |  | stability tests, if appropriate.                                       | All intravenous & injectables.                                 |  |
| To Diotomy Secondary 10   | To Health Feeds & D   | D 7  | To Outhodox N-t1 D 'C  | To Complement M-31-1 16  |  |
| To <b>D</b> ietary <b>S</b> upplements if <b>HFB</b> parameters exceeded to | To Health Foods & Beverages if abandon DS & meet HFB                  | Product Padagification   | To Orthodox Natural Drugs if above-mentioned parameters                | To Complementary Medicine if not for above-mentioned use, &    |  |
| infringe on delineated <b>DS</b>  | delineated parameters. Requires                                       | Reclassification (1 stage)                                     | exceeded to infringe on <b>OND</b>                                     | claims or risks do not exceed                                  |  |
| substance parameters.   | <u>complete product name-change</u> .  ←                              | (I stage)  | delineated parameters.   | CM or meet OND parameters.  ←                                  |  |
| ,   | `   | Product  |  | ·  |  |
| To Complementary Medicines if specifically <b>pharmaco</b> -                | To Complementary Medicines  | Reclassification   | To <b>D</b> ietary Supplements if abandon <b>CM</b> & meet <b>DS</b>   | To Dietary Supplements if                                      |  |
| logical in action, or high  | if <b>DS</b> parameters exceeded to infringe on <b>CM</b> parameters. |  | delineated parameters. Requires  | abandon <b>OND</b> & <b>CM</b> delineated parameters. Requires |  |
| adverse reaction risk.  | →→  | (2 stage)  | complete product name change.  | complete product name change.                                  |  |
| $\longrightarrow \longrightarrow$   |   | Duo 34   | <b>←</b> ←   | <b>←</b> ←   |  |
| To Orthodox Natural Drugs if  | To Orthodox Natural Drugs if  | Product Reclassification                                       | To <b>H</b> ealth <b>F</b> oods & <b>B</b> everages if                 | To Health Foods & Beverages if                                 |  |
| significantly high  | significantly high  | Acciussification   | abandon CM & meet HBS  | abandon OND & meet HBS   |  |
| life-threatening adverse reactions risk.                                    | life-threatening adverse reactions risk.                              | (3 stage)  | delineated parameters. Requires complete product name change.          | delineated parameters. Requires complete product name change.  |  |
| $\rightarrow \rightarrow \rightarrow$                                       | $\rightarrow \rightarrow \rightarrow$                                 |  | <u>complete product name enange</u> . <b>←</b> ←←                      | <u>complete product name enange</u> . <b>←←←</b>               |  |
|   |   |  |  |  |  |